David Gray

David joins Inscopix from CNS-focused drug development company Cerevel Therapeutics, where as a founding individual and Vice President of Chemistry had responsibility for intellectual property, and co-led several late-stage clinical programs.During the past eight years, Dr. Gray has been spearheading clinical programs aimed to create improved motor symptom therapies in Parkinson’s disease and treatments for specific cognitive and motivational deficits associated with schizophrenia, Alzheimer’s and other CNS diseases. He led the early research and then the clinical development of a series of D1 partial agonists which include tavapadon, currently in Ph3. He is active in several patient and pre-competitive CNS research communities and has over 50 peer reviewed publications spanning a wide variety of scientific disciplines. David holds a PhD in organic chemistry from The Scripps Research Institute, following which he had a illustrious career at Pfizer, starting as a medicinal chemist then transitioning to leadership roles in the CNS biology department where his group was responsible for human-relevant assay development and translational neuroscience in the areas of depression, schizophrenia, Alzheimer’s and Parkinson’s.